Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)

Innoviva (INVA) posted Non-Current Deferred Tax Liability of $72.8 million for Q1 2026, up 129.08% on a QoQ basis from $31.8 million in Q4 2025.

Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends

Innoviva's Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $72.8 million for Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (changed N/A YoY) and the FY2025 annual result came in at $31.8 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability was $72.8 million for Q1 2026 at Innoviva, up from $31.8 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $72.8 million in Q1 2026 and bottomed at $563000.0 in Q4 2023.
  • A 5-year average of $20.0 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability tumbled 90.24% — and 2024, when it dropped 29.4%.
  • Innoviva's Non-Current Deferred Tax Liability stood at $5.8 million in 2022, then tumbled by 90.24% to $563000.0 in 2023, then soared by 576.2% to $3.8 million in 2024, then surged by 735.12% to $31.8 million in 2025, then surged by 129.08% to $72.8 million in 2026.
  • Business Quant data shows INVA's Non-Current Deferred Tax Liability at $72.8 million in Q1 2026, $31.8 million in Q4 2025, and $3.8 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Innoviva 1.57 Bn 969.11 Mn 75.83 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 72.83 Mn
Mar 31, 2026 72.83 Mn
Dec 31, 2025 31.79 Mn
Dec 31, 2025 31.79 Mn
Mar 31, 2024 3.81 Mn
Mar 31, 2024 3.81 Mn
Dec 31, 2023 563,000.00
Dec 31, 2023 563,000.00
Mar 31, 2023 5.39 Mn
Mar 31, 2023 5.39 Mn
Dec 31, 2022 5.77 Mn
Dec 31, 2022 5.77 Mn